Is it time for vaccination mandates?

World of DTC Marketing

29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates?

Profiteering off a Covid vaccine

World of DTC Marketing

SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine.


Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The Covid-19 vaccine numbers game

World of DTC Marketing

SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine

Consumers fall into three COVID-19 vaccine adoption segments

World of DTC Marketing

(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine

Optimism on Pfizer COVID vaccine is unwarranted

World of DTC Marketing

You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.

What DTC marketers can learn from people who refuse a COVID vaccination

World of DTC Marketing

SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine.

Moderna puts seasonal flu vaccine ambitions to the test

Bio Pharma Dive

Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus

Flu Vaccine vs. COVID-19 Vaccine

My Local Study

These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on

Covid vaccine profits and the strain on supply channels

World of DTC Marketing

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.

FDA flags rare side effect in new warning on J&J's coronavirus vaccine

Bio Pharma Dive

The agency said the benefits of vaccination with J&J's shot still "clearly outweigh" the risks, which now include very rare cases of a immune-driven condition known as Guillain-Barré

Merck stops coronavirus vaccine development in surprise setback

Bio Pharma Dive

The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials

Coronavirus vaccine from Pfizer, BioNTech prevents COVID-19, early results show

Bio Pharma Dive

An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective

HIV Vaccine Awareness Day

Pharma R&D Today

The global focus on the development and distribution of COVID-19 vaccines over the past year has been a reminder that there are still many other diseases for which the world has long sought a vaccine. International large-scale vaccine studies.

COVID-19 vaccine: A hope and prayer?

World of DTC Marketing

QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?”

Advantages of intranasal vaccination against SARS-CoV-2


Intranasal vaccination is needle-free and elicits immunity at the site of infection, the respiratory tract Credit: UAB BIRMINGHAM, Ala.

FDA authorizes J&J's one-shot coronavirus vaccine

Bio Pharma Dive

The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time

Novavax says vaccine 90% effective against COVID-19 in large trial

Bio Pharma Dive

Highly anticipated results from a Phase 3 study testing the biotech company's shot showed it to be strongly protective and safe, a potential boon for the world's vaccination efforts

Trials 182

COVID 19 vaccine means big money and greed

World of DTC Marketing

QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine

FDA authorizes Pfizer's coronavirus vaccine for younger teens

Bio Pharma Dive

The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand

Pfizer set to double weekly production of coronavirus vaccine

Bio Pharma Dive

The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday

UK authorizes AstraZeneca, Oxford coronavirus vaccine, but questions linger

Bio Pharma Dive

The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it

Vaccine sales driven down by pandemic's effects on doctor visits

Bio Pharma Dive

Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations

FDA advisers meet to review Pfizer, BioNTech's coronavirus vaccine

Bio Pharma Dive

A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here

Pfizer forecasts $26B in coronavirus vaccine revenue this year

Bio Pharma Dive

The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year

Will people line up for a COVID-19 vaccine?

World of DTC Marketing

QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine

BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

Bio Pharma Dive

Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent

FDA review supports safety, efficacy of J&J coronavirus vaccine

Bio Pharma Dive

Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency

Biden Backs Suspending Patents on Covid Vaccines

NY Times

pharmaceutical industry, came out in favor of waiving intellectual property protections for coronavirus vaccines. The Biden administration, siding with some world leaders over the U.S.

The FDA Should Fully Approve Pfizer and Moderna's Vaccines

NY Times

The Pfizer and Moderna vaccines are safe and effective. Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Food and Drug AdministrationFull approval from the F.D.A. will help stop the spread of Covid-19.

GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations

BioTech 365

GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations GEHA Extends Vaccination Incentive Program to Encourage U.S. COVID-19 Vaccinations GEHA Vaccination Incentive Program Extended to September 6, 2021 LEE’S SUMMIT, Mo.–(BUSINESS

The waiver on COVID vaccine patents is not about the vaccine

World of DTC Marketing

IT’S FRIDAY: The Biden administration’s decision to support a temporary waiver of Covid-19 vaccine patents prompted instant and false outrage in pharma. With the new mRNA vaccines made by Pfizer and Moderna, it may take longer.

Vaccine makers prepare response as coronavirus mutations raise alarms

Bio Pharma Dive

So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't

As COVID-19 becomes a business, vaccine makers confront thorny pricing questions

Bio Pharma Dive

Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots

Study finds vaccine hesitancy lower in poorer countries


Infectious Emerging Diseases Collaboration Disease in the Developing World Epidemiology Infectious/Emerging Diseases Medical/Scientific Ethics Medicine/Health Public Health Vaccines

Moderna plans triple vaccine targeting flu, COVID and RSV

Pharma Phorum

Buoyed by the success of its COVID-19 vaccine, Moderna has started a phase 1/2 trials of its mRNA-based shot for seasonal influenza, targeting four different flu strains. . They could offer a more potent option to conventional flu shots, according to mRNA vaccine developers.

Researchers lay out hypothesis for rare side effect linked to AstraZeneca vaccine

Bio Pharma Dive

The EMA has reiterated the benefits of the shot outweigh the risks, but the safety concerns are another hurdle to the vaccine's rollout in Europe

As trials progress, FDA weighs COVID-19 vaccine authorizations for children

Bio Pharma Dive

Some experts argued falling infection rates might mean vaccination of kids under 12 is unnecessary An advisory panel could not reach consensus on how long or large trials in young children should be.

Trials 153

Pfizer, BioNTech ink vaccine supply deal for Africa in step toward addressing criticism

Bio Pharma Dive

The companies aim to deliver 100 million doses per year to 55 African countries in an effort to shrink the wide gap between high- and lower-income countries in coronavirus vaccinations

Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses

Bio Pharma Dive

The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 100 million doses of Pfizer and BioNTech's vaccine for supply in Europe

Coronavirus vaccine makers Oxford, Novavax follow up with a promising malaria shot

Bio Pharma Dive

A vaccine co-developed by the U.K. academic center and the Maryland biotech could be the first to meet the WHO's efficacy target for a malaria vaccine

Novartis joins Sanofi in aiding manufacture of coronavirus vaccines

Bio Pharma Dive

A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments

Blaming the anti-vaxxers is not the answer

World of DTC Marketing

There are many reasons why people aren’t getting vaccinated. Until we have more data to really understand why people are getting vaccinated against COVID, we shouldn’t fall into the trap of blame. There are potentially many reasons why people haven’t been vaccinated.

Manufacturing mix-up could blunt supply boost from J&J vaccine

Bio Pharma Dive

One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses